Dr. Masarova on Future Research in MPNs

Lucia Masarova, MD, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses future research ​efforts in myeloproliferative neoplasms (MPNs).

With multiple encouraging studies and investigational agents in the pipeline, the MPN space ​appears to be entering an exciting era, says Masarova.

Notably, the field is anticipating additional data with other JAK inhibitors ​beyond ruxolitinib (Jakafi) and fedratinib (Inrebic), ​Masrova explains.

Additionally, findings regarding targeted agents and novel combination therapies ​with JAK inhibitors ​are poised to read out at a future medical meeting, Masrova concludes.